MODERNA: HIV Vaccine in Trials


A blood sample being held with a row of human samples for analytical testing including blood, urine, chemistry, proteins, anticoagulants and HIV in lab

Moderna has begun early-stage trials for an mRNA-based HIV vaccine -- that's the same technology it used for its COVID shot. 56 people have entered this phase 1 trial, and 48 of them will get the vaccine.Photo: Cultura RF

TeeRoy's 2 Cents:

If the mRNA technology works, some credit has to go to President Trump. Without his push for the COVID vaccine, this might not have happened.

Even though HIV is now a manageable disease, it'd much better not to get it at all.

Phase 1 trials focus primarily on safety, which is why they are so small.

I wonder how long the efficacy will last. Hopefully longer than the COVID vaccine.

Unfortunately, if it has to be kept at ultra-cold temperatures, it will be difficult to distribute in much of Africa, where AIDS still runs rampant.

We may have just taken the first step in ending the HIV-AIDS crisis.

Moderna has begun early-stage trials for an mRNA-based HIV vaccine -- that's the same technology it used for its COVID shot. 56 people have entered this phase 1 trial, and 48 of them will get the vaccine. Of them, 32 will get a booster shot. They will be monitored for at least six months.

Although treatments have made HIV much more manageable than when it first emerged, a vaccine has never been developed. (ABC News)


Sponsored Content

Sponsored Content